2010 FDA Advisory Committees
You may also be interested in...
Where FDA Is Paying The Most Attention: Drug Safety Advisory Committee Had The Most Meetings In 2010
FDA’s ongoing efforts to ramp up its focus on drug safety are being borne out at the advisory committee level, which saw a doubling in the number of meeting days for the Drug Safety and Risk Management Advisory Committee in 2010.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: safety debate as more lecanemab data reported; amyloid discussions continue at Alzheimer’s meeting; China COVID unrest affect country’s biotech sector; and Merck’s CMO talks about post-Keytruda plans.